title: Anticalcification and antiresorption effects of bisacylphosphonates.
abstract: Some geminal bisphosphonates are used clinically in a number of important bone and calcium-related diseases. This work reports the anticalcification and antiresorption effects of a series of bisacylphosphonates, nongeminal compounds with varying chain lengths having oxo groups in alpha positions relative to the phosphonic functions. We compared the activity of the novel compounds to clinically used geminal bisphosphonates, and to a bisphosphonate devoid of the oxo groups. The interaction of the compounds with calcium was studied by various in vitro and in vivo models. We found that keto groups in alpha positions to the phosphonic functions render activity. The bisacylphosphonates with a shorter chain [(CH2)n, = 4, 6] were found significantly to inhibit hydroxyapatite formation and dissolution in vitro, the calcification of bioprosthetic tissue implanted subdermally in rats, and bone resorption in the intact young animal model. The various in vitro results were found to be in good correlation with the in vivo results. Structure-activity relationship studies indicate that both bisacylphosphonates and geminal bisphosphonates are active only when at least three ionizable groups are present in the molecule. The role of the keto groups is related to their contribution to chelating calcium and/or to their electron-withdrawing influence on acidity.
authors.affiliation: Department of Pharmacy, School of Pharmacy, Hebrew University of Jerusalem, Israel.
authors.forename: J M
authors.initials: JM
authors.lastname: Van Gelder
authors.forename: E
authors.initials: E
authors.lastname: Breuer
authors.forename: A
authors.initials: A
authors.lastname: Ornoy
authors.forename: A
authors.initials: A
authors.lastname: Schlossman
authors.forename: N
authors.initials: N
authors.lastname: Patlas
authors.forename: G
authors.initials: G
authors.lastname: Golomb
mesh_terms: D000215:Acylation; D000327:Adsorption; D000818:Animals; D001862:Bone Resorption / Q000188:drug therapy*; D002114:Calcinosis / Q000188:drug therapy*; D003198:Computer Simulation; D004164:Diphosphonates / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005260:Female; D006351:Heart Valves / Q000187:drug effects / Q000378:metabolism; D007659:Ketones / Q000737:chemistry; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D009682:Magnetic Resonance Spectroscopy; D008958:Models, Molecular; D051381:Rats; D013054:Spectrophotometry, Atomic; D013329:Structure-Activity Relationship; D013977:Tibia / Q000187:drug effects / Q000378:metabolism
chemical_list: D004164:Diphosphonates; D007659:Ketones